Several myositis-specific antibodies have been recently reported in patients with IIMs, including transcription intermediary factor 1 gamma (TIF1γ), Mi-2, small ubiquitin-like modifier activating enzyme (SAE), aminoacyl-transfer (t)RNA synthetases (ARS) including anti-Jo-1, and MDA5 [6]. This evidence concerns the gene TRIM33 and myositis disease.